Expanding precision medicine

“This really is the perfect job for me”

Chronic neurological conditions affect many people. Diagnostics and therapeutics companies are pooling their strengths to accelerate progress. Our colleague Aileen Shields supports them and works in our Center for Innovation in Diagnostics (CID) CLIA laboratory in Berkeley, California, looking at ways of improving the treatment of multiple sclerosis.

4min

Meike Feder and Doris Pischitz

Published on May 19, 2022

Focus on multiple sclerosis

Elevated levels in CSF and blood of the NfL protein - infographic

Elevated levels in CSF and blood of the NfL protein contained in myelinated axons are a sign of neuronal injury.

Source: Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(19):577–589.

Pooling strengths to accelerate progress

What is.... ?

Our lab in Berkeley and our colleagues there

Berkeley Lab outside view — High-complexity CLIA (specially licensed) laboratory
75,000 sq. ft. facility and laboratory space in Berkeley, CA
SHL R&D team with expertise in biomarker discovery, assay development, and data analytics

By Meike Feder and Doris Pischitz

Source: [1] Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954–963.
Disclaimer: 1 NfL is not available for sale for routine clinical use for patient management purposes. The NfL testing service for use in clinical trials is available from Siemens Healthcare Laboratory in Berkeley, California. 2 The product/feature and/or service offerings (mentioned herein) are not commercially available in all countries and/or for all modalities. Their future availability cannot be guaranteed.